New NHS Weight Management Medication – Tirzepatide (Mounjaro®)

Posted on:

NHS England and NICE have approved the use of Tirzepatide, also known as Mounjaro® or sometimes referred to as ‘the weight loss drug’, for use in primary care.

You may hear that Tirzepatide will be available from primary care starting 23rd June 2025. However, NHS England has introduced strict eligibility criteria for the first two years to ensure the safe and controlled rollout of this medicine.

Please only contact the practice if you meet both of the following:

  • You have a BMI of 40 or higher
  • You have already been diagnosed with at least four of the following conditions by your GP or another medical professional:
  1. Hypertension
  2. Dyslipidaemia
  3. Obstructive sleep apnoea
  4. Atherosclerotic Cardiovascular Disease (ASCVD)
  5. Type 2 diabetes mellitus

For patients who meet the eligibility criteria above in discussion with your GP a decision will be made whether or not Tirzepatide is the best treatment for you. If it is agreed that Tirzepatide is the right choice you will also be required to agree to engage with behavioural support and wraparound care.

Additional media assets:

There are a range of NHS social media assets and other communication assets on the DHSC website here From 23 June, people living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings. | Help Us Help You – Primary Care Services | Campaign Resource Centre

👉 For more information and FAQs, click here.